Acadesine
| CAS No. | 2627-69-2 | Cat. No. | BCP06900 |
| Name | Acadesine | ||
| Synonyms | GP 1 110; ARA100; ARA-100; ARA 100; SCH-900395; SCH 900395; SCH900395; AICA ribofuranoside;AICAR; AICA-riboside; | ||
| Formula | C9H14N4O5 | M. Wt | 258.23 |
| Description | AICAR is an AMP-activated protein kinase activator which is used for the treatment of acute lymphoblastic leukemia[2] and may have applications in treating other disorders such as diabetes. Acadesine is an adenosine regulating agent developed by PeriCor Therapeutics and licensed to Schering-Plough in 2007 for phase III studies. The drug is a potential first-in-class agent for prevention of reperfusion injury in CABG surgery. Schering began patient enrollment in phase III studies in May, 2009. The trial was terminated in late 2010 based on an interim futility analysis. | ||
| Pathways | PI3K/Akt/mTOR Epigenetics | ||
| Targets | AMPK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.